Is Akebia Ther (AKBA) overvalued? · rev $160.2M
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Akebia Ther (AKBA) looks expensive on cached numbers — not a short thesis.
Latest reported AKBA revenue for 2024-12-31 was $160.2M. Net income was -$69.4M. Revenue was down 17.7% from 2023-12-31 to 2024-12-31. AKBA currently screens at market cap $260.1M.
AKBA currently screens at market cap $260.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AKBA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AKBA stock page for the full model, not this heading.
Not investment advice.